Affiliation:
1. School of Life Science and Technology, Wuhan Polytechnic University, Wuhan 430023, China
2. State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan 430062, China
Abstract
Kidney renal papillary cell carcinoma (KIRP) is a highly heterogeneous type of kidney cancer, resulting in limited effective prognostic targets for KIRP patients. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in the regulation of ferroptosis and iron metabolism, making them potential targets for the treatment and prognosis of KIRP. In this study, we constructed a ferroptosis-related lncRNA risk score model (FRM) based on the TCGA-KIRP dataset, which represents a novel subtype of KIRP not previously reported. The model demonstrated promising diagnostic accuracy and holds potential for clinical translation. We observed significant differences in metabolic activities, immune microenvironment, mutation landscape, ferroptosis sensitivity, and drug sensitivity between different risk groups. The high-risk groups exhibit significantly higher fractions of cancer-associated fibroblasts (CAFs), hematopoietic stem cells (HSC), and pericytes. Drugs (IC50) analysis provided a range of medication options based on different FRM typing. Additionally, we employed single-cell transcriptomics to further analyze the impact of immune invasion on the occurrence and development of KIRP. Overall, we have developed an accurate prognostic model based on the expression patterns of ferroptosis-related lncRNAs for KIRP. This model has the potential to contribute to the evaluation of patient prognosis, molecular characteristics, and treatment modalities, and can be further translated into clinical applications.
Funder
major scientific and technological research project of Tianjin
central government guides local science and technology development projects
Open Funding Project of the State Key Laboratory of Biocatalysis and Enzyme Engineering
Research and Innovation Initiatives
Reference69 articles.
1. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma;Linehan;N. Engl. J. Med.,2016
2. Utilization of Sunitinib for Renal Cell Cancer: An Egyptian University hospital experience;Asian Pac. J. Cancer Prev.,2016
3. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: A meta-analysis and review;Kim;Oncotarget,2017
4. A phase I study of cabozantinib (XL184) in patients with renal cell cancer;Choueiri;Ann. Oncol.,2014
5. Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors;Delahunt;Mod. Pathol.,1997